Related Experiment Video
Updated: May 5, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
Published on: June 26, 2014
Hepatitis C virus inhibits interferon signaling through up-regulation of protein phosphatase 2A
Francois H T Duong1, Magdalena Filipowicz, Marco Tripodi
1Department of Research, University Hospital Basel, Basel, Switzerland.
Background And Aims:
To establish a chronic infection, hepatitis C virus (HCV) has to evade the host defense. Expression of HCV proteins in cultured cells and in hepatocytes of transgenic mice inhibits interferon-alpha-induced intracellular signaling through the Jak-STAT (signal transducer and activator of transcription) pathway. It is not known if interferon-alpha signaling is inhibited in patients with chronic hepatitis C as well, and the molecular mechanisms are not well defined.
Methods:
Interferon-alpha-induced signaling was investigated in liver biopsies from patients with chronic hepatitis C. The molecular mechanisms of HCV interference with Jak-STAT signaling were analyzed in cultured cells, HCV transgenic mice, and liver biopsies.
Results:
Interferon-alpha-induced DNA binding of STAT1 was significantly impaired in liver biopsies from patients with chronic hepatitis C compared with controls. Tyrosine and serine phosphorylation of STAT1 were intact, but methylation of STAT1 on arginine 31 was reduced. Hypomethylated STAT1 associated with PIAS1, an inhibitor of STAT DNA binding. Increased expression levels of Protein Phosphatase 2A were found in liver extracts from HCV transgenic mice and in liver biopsies of patients with chronic hepatitis C. Overexpression of PP2Ac in Huh7 cells resulted in hypomethylation of STAT1, increased binding to PIAS1, and reduced interferon-alpha-induced DNA binding of STAT1.
Conclusions:
We conclude that HCV interferes with interferon-alpha signaling via up-regulation of PP2Ac, hypomethylation of STAT1, and increased STAT1-PIAS1 association, resulting in reduced transcriptional activation of interferon-alpha-stimulated genes.
Insights
Hepatitis C virus (HCV) impairs interferon-alpha signaling in chronic hepatitis C patients by upregulating PP2Ac, leading to STAT1 hypomethylation and reduced gene activation. This explains a key viral immune evasion mechanism.
Area of Science:
- Hepatology
- Virology
- Immunology
Background:
- Hepatitis C virus (HCV) evades host defenses to establish chronic infection.
- HCV proteins inhibit interferon-alpha-induced Jak-STAT signaling in cell cultures and transgenic mice.
- The inhibition of interferon-alpha signaling in chronic hepatitis C patients and its mechanisms remain unclear.
Purpose of the Study:
- To investigate interferon-alpha signaling in liver biopsies from chronic hepatitis C patients.
- To elucidate the molecular mechanisms by which HCV interferes with Jak-STAT signaling.
Main Methods:
- Analysis of interferon-alpha-induced signaling in liver biopsies from chronic hepatitis C patients and controls.
- Investigation of molecular mechanisms in cultured cells, HCV transgenic mice, and patient liver biopsies.
- Assessment of STAT1 phosphorylation, methylation, and association with PIAS1.
- Quantification of Protein Phosphatase 2A (PP2Ac) expression levels.
Main Results:
- STAT1 DNA binding was impaired in chronic hepatitis C patients.
- STAT1 phosphorylation was intact, but arginine 31 methylation was reduced, leading to hypomethylation.
- Hypomethylated STAT1 showed increased association with PIAS1, an inhibitor of STAT DNA binding.
- Increased PP2Ac expression was observed in HCV transgenic mice and chronic hepatitis C patients.
- Overexpression of PP2Ac in cells mimicked the effects on STAT1 and interferon-alpha signaling.
Conclusions:
- HCV interferes with interferon-alpha signaling through PP2Ac upregulation and STAT1 hypomethylation.
- This leads to increased STAT1-PIAS1 association, inhibiting STAT1 DNA binding.
- Reduced transcriptional activation of interferon-alpha-stimulated genes is a consequence of this interference.
Related Concept Videos
The JAK-STAT Signaling Pathway
Hepatitis
Inhibitors of Viral Protein Synthesis
Gastritis II: Pathophysiology
Viral Hepatitis I: Introduction
Cirrhosis II: Pathophysiology

